NTRB

NTRB is not really a $2M-revenue medical-supply company; it is a single-asset clinical bet dressed in a tiny contract-manufacturing shell. The MD&A is explicit that the whole story is AVERSA Fentanyl, an abuse-deterrent transdermal drug-device combination that 'will require approval from the FDA and substantial capital,' and that management needs 'approximately $13 million' — possibly 'substantially in excess of that amount' — to complete clinical work at contract manufacturer Kindeva. The real business (Pocono tape/contract manufacturing) generated $2.04M of revenue (down 4.8% YoY) at just 27.8% gross margin, and the 4P Therapeutics segment booked $0 as its main contract wound down. So the durable operating business is shrinking, sub-scale, and barely gross-profitable ($566K), while the company reported an $8.23M net loss and a -$5.13M operating cash outflow.

The balance sheet is clean of debt (liabilities/equity 0.13x) but that is cold comfort: cash is only $4.57M against a $5.1M annual operating burn — well under a year of runway — and a $13M development bill still ahead. That gap can only be closed with equity, and the filing already shows the mechanism at work: shares grew 9% YoY, SG&A jumped to $6.99M from $4.31M 'primarily due to an increase in equity-based expenses' (warrants and options), and the accumulated deficit has ballooned to -$46.7M. Diluted EPS was -$2.58. This is a serial diluter with no path to self-funding, so existing holders face structural, ongoing erosion regardless of clinical outcome.